Patents Examined by Barry A Chestnut
  • Patent number: 11951163
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 9, 2024
    Assignee: Valneva Austria GMBH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 11945849
    Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: April 2, 2024
    Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
  • Patent number: 11946066
    Abstract: Disclosed herein include methods, compositions, and systems suitable for use in delivering a polynucleotide to a target cell of a subject in need thereof. In some embodiments, a viral vector comprises a polynucleotide encoding nucleoprotein (N), phosphoprotein (P), matrix protein (M), RNA-dependent RNA polymerase (L), and one or more transgenes. The viral vector can comprise one or more of a conditionally stable fusion protein, a protease fusion protein, a degron fusion protein, and/or a glycoprotein derived of another species than the viral vector polynucleotide to enable control of viral vector transduction and/or replication.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: April 2, 2024
    Assignee: California Institute of Technology
    Inventors: Xiaojing Gao, Lucy S. Chong, Michael B. Elowitz, Matthew S-M Kim
  • Patent number: 11944678
    Abstract: The present disclosure provides for systems and methods for targeted mass inoculation. A transmission system for targeted mass inoculation may comprise a first pathogen, wherein first pathogen may comprise a vaccination for an infectious disease. The transmission system may comprise a host that receives the first pathogen. The transmission system may comprise a vector that receives a second pathogen from the host. The second pathogen may inoculate a secondary host when the secondary host receives the second pathogen from the vector. The vector may comprise a mechanical device. When the vector comprises a mechanical device, the vector may comprise a computing device. The computing device may identify a suitable secondary host. The computing device may comprise an algorithm for secondary host recognition and differentiation. The computing device may retain a database comprising indicators of which secondary host candidates have already received the pathogen.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: April 2, 2024
    Assignee: Ending Patient Zero, LLC
    Inventors: Sarah Rose Wicker, Mary Kathryn Reynolds
  • Patent number: 11940449
    Abstract: Compositions and methods for immunological detection of coronavirus antibodies are provided.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: March 26, 2024
    Assignee: ID-Fish Technology, Inc.
    Inventors: Jyotsna S. Shah, Song Liu, Hari-Hara Potula, Prerna Bhargava
  • Patent number: 11938196
    Abstract: This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and/or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.
    Type: Grant
    Filed: May 11, 2023
    Date of Patent: March 26, 2024
    Inventor: Paul Alexander Heppenstall
  • Patent number: 11926648
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: March 12, 2024
    Inventors: Felix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Patent number: 11920150
    Abstract: Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: March 5, 2024
    Assignees: The Broad Institute, Inc., President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Pardis Sabeti, Mohammadsharif Tabebordbar, Simon Ye
  • Patent number: 11920165
    Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: March 5, 2024
    Assignee: Baylor College of Medicine
    Inventors: Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
  • Patent number: 11918641
    Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 5, 2024
    Inventors: Chi-Huey Wong, Hsin-Yu Liao, Shih-Chi Wang, Yi-An Ko, Kuo-I Lin, Che Ma, Ting-Jen Cheng
  • Patent number: 11911461
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a SARS-CoV-2 variant C.1.2 modified S1 Spike protein sequence and a non-phospholipid liposome, wherein the protein is encapsulated within the non-phospholipid liposome. The adjuvanted protein vaccines are suitable for subcutaneous administration. Also disclosed herein are modified spike protein sequences containing SARS-CoV-2 variant C.1.2 modified S1 Spike proteins and methods of use of the vaccines and sequences.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: February 27, 2024
    Assignee: D4 Labs, LLC
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko
  • Patent number: 11904012
    Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: February 20, 2024
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
  • Patent number: 11905314
    Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: February 20, 2024
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Ferdinand Jacobus Milder, Tina Ritschel, Boerries Brandenburg, Mandy Antonia Catharina Jongeneelen, Daphné Truan, Johannes Petrus Maria Langedijk
  • Patent number: 11896658
    Abstract: Recombinant, live, attenuated viruses of the Pneumoviridae family are disclosed that include a baculovirus GP64 envelope glycoprotein or variant or fragment thereof and a respiratory syncytial virus (RSV) F protein variant or fragment thereof. Also disclosed are polynucleotides encoding the virus as well as pharmaceutical compositions and vaccines containing the virus. In addition, methods of producing and using each of the above compositions are also disclosed.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: February 13, 2024
    Assignee: Board of Regents for Oklahoma State University
    Inventor: Antonius G. P. Oomens
  • Patent number: 11890337
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: February 6, 2024
    Assignee: Children's Hospital Medical Center
    Inventors: Karnail Singh, Paul Spearman
  • Patent number: 11884939
    Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA?C7L and VACV?C7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA?C7L or VACV?C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: January 30, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Ning Yang, Taha Merghoub, Jedd Wolchok
  • Patent number: 11883487
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: January 30, 2024
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • Patent number: 11883479
    Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: January 30, 2024
    Assignees: GENEXINE, INC., MSD International GmbH
    Inventors: Young Chul Sung, Jung Won Woo, Jong Sup Park, Jin Won Youn
  • Patent number: 11878055
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
    Type: Grant
    Filed: June 26, 2023
    Date of Patent: January 23, 2024
    Assignee: BioNTech SE
    Inventors: Alexander Muik, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
  • Patent number: 11872276
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue virus (DENV) infections in a human subject.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: January 16, 2024
    Inventors: Claude Roth, Etienne Simon-Loriere, Anavaj Sakuntabhai, Felix Delgado